Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

Global & Regional Health Technology Assessment

Marcello Pani¹  Claudio Jommi²  Antonio Addis³  Elena Nicod⁴  Nello Martini⁵  Annalisa Scopinaro⁶  Sabine Vogler⁷ 

[1] Agostino Gemelli IRCCS University Hospital Foundation, Rome - Italy;Cergas SDA Bocconi School of Management, Milan - Italy;Department of Epidemiology, Regional Health Service (Regione Lazio) Member of the Scientific Technical Committee, Italian Medicines Agency (AIFA), Rome - Italy;Dolon Ltd, London - UK and Cergas SDA Bocconi School of Management, Milan - Italy;Fondazione ReS (Research and Health Foundation), Rome - Italy;UNIAMO (Italian Federation for Rare Diseases), Rome - Italy;WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Austrian National Public Health Institute (GÖG), Vienna - Austria;

关键词: Italy;    Managed entry agreements;    Orphan medicines;    Value framework;   

DOI  :  10.33393/grhta.2021.2278

来源: DOAJ

【 授权许可】

Unknown